GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey

The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.

The FDA approved GSK's Ojjaara for myelofibrosis with anemia • Source: Shutterstock

More from New Products

More from Scrip